August 27, 2015 – DelMar Pharmaceuticals Inc.
VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2015 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it will release its year-end financial results for the fiscal year ending June 30, 2015 on Friday, September 4, 2015. DelMar’s management team will host a business update conference call and live webcast for investors, analysts and other interested parties on Friday, September 4, 2015, at 11:00 a.m. EDT / 8:00 a.m. PDT. During the business update call, management will discuss recent corporate highlights including the Company’s progress of its Phase II clinical trial of VAL-083 (dianhydrogalactitol) for the treatment of refractory glioblastoma multiforme (GBM) and corporate goals for the upcoming year including plans to advance VAL-083 into registration-directed Phase II/III clinical trials in refractory GBM as well as initiate new clinical trials with VAL-083 as a potential treatment for non-small cell lung cancer (NSCLC) and other solid tumors. Conference Call Details The DelMar business update conference call and live webcast is scheduled for Friday, September 4, 2015, beginning at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. For both “listen-only” participants and those who wish to take part in the question and answer portion of the call, the telephone Dial-in Number is (866) 394-9399 (toll-free) with Conference ID 22042321. A link to the webcast and slides will be available on the IR Calendar of the Investors section of the Company’s website at www.delmarpharma.com, and will be archived for 30 days. Webcast participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. About DelMar Pharmaceuticals, Inc. DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients. For further information, please visit here DelMar Pharmaceuticals Investor Relations: email@example.com Phone: (604) 629-5989 Follow us on: Twitter @DelMarPharma or Facebook.com/delmarpharma. Investor Relations Counsel: Amato & Partners LLC. Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. To view the original version on PR Newswire, please visit here.